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Conservative	 management	 of	 both	 abnormally	 adherent	 (placenta	
creta)	and	invasive	placenta	(placenta	 increta	and	percreta)	defines	
all	 procedures	 that	 aim	 to	 avoid	 peripartum	 hysterectomy	 and	 its	
related	morbidity	and	consequences.	Four	different	primary	meth-
ods	of	conservative	management	have	been	described	in	the	inter-
national	 literature:	 (1)	 the	 extirpative	 technique	 (manual	 removal	
of	 the	 placenta);	 (2)	 leaving	 the	 placenta	 in	 situ	 or	 the	 expectant	
approach;	(3)	one-	step	conservative	surgery	(removal	of	the	accreta	
area);	 and	 (4)	 the	 Triple-	P	 procedure	 (suturing	 around	 the	 accreta	
area	 after	 resection).	 These	 methods	 have	 been	 used	 alone	 or	 in	
combination	and	in	many	cases	with	additional	procedures	such	as	
those	proposed	by	interventional	radiology.
The	main	 aim	of	 leaving	 the	placenta	 in	 situ	versus	 the	extirpa-
tive	method	is	essentially	to	attempt	to	decrease	the	risks	of	severe	





increasing	 the	 risk	of	 injuries	mainly	 to	 the	bladder	and	ureters	and	
their	possible	long-	term	complications	such	as	vesicouterine	fistula.1–4 




in	 selecting	 the	most	 appropriate	 conservative	 treatment	 option	 to	
manage	women	with	the	different	types	of	placenta	accreta	spectrum	
(PAS)		disorders	according	to	their	individual	need	and	the	local	exper-
tise	of	 the	 healthcare	 team.	 Since	 histopathological	 confirmation	of	
adherent	or	 invasive	placentation	is	rarely	available	 in	most	cases	of	
conservative	management	 and	 few	 authors	 provide	 detailed	 clinical	
information	on	 the	differential	 diagnosis	 between	 retained	placenta	
and	abnormally	adherent	placenta	or	the	depth	and	lateral	extension	
of	 accreta	 placentation,	we	use	 the	 term	PAS	disorders	 to	describe	
both	adherent	and	invasive	placentation.	When	available	we	refer	to	
the	different	depth	of	PAS	disorders,	i.e.	creta,	increta,	and	percreta.





to	manage	postpartum	hemorrhage.6–13 However, in cases of PAS disor-
ders,	this	procedure	often	results	in	massive	obstetric	hemorrhage	and,	





amount of red blood cells transfused, disseminated intravascular coag-
ulation,	hysterectomy	rates,	and	secondary	maternal	infection	during	
the	second	period	when	the	placenta	was	left	in	situ	compared	with	
the	first	period	when	 the	placenta	was	always	 removed	manually.14 
PAS	disorders	were	diagnosed	in	the	51	cases	included	in	this	study	
using	the	following	clinical	criteria:
1.	 Manual	 removal	 of	 the	 placenta	 partially	 or	 totally	 impossible	





4.	 Histologic	 confirmation	 of	 PAS	 disorders	 on	 a	 hysterectomy	
specimen.
Overall,	most	experts	 in	 the	management	of	PAS	disorders	con-
sider	 that	 attempts	 at	 manual	 removal	 of	 the	 placenta	 should	 be	





















for	 invasive	 accreta	 but	 it	 remains	 associated	 with	 high	 rates	
(40%–50%)	 of	 severe	 maternal	 morbidity	 and,	 in	 cases	 of	 pla-
centa	 percreta,	 the	mortality	 rates	 can	 be	 as	 high	 as	 7%	 owing	
to damage to pelvic organs and vasculature.
2.	 The	extirpative	method	is	associated	with	severe	maternal	morbid-
ity	 because	 it	 leaves,	 within	 the	 myometrium,	 placental	 tissues	




uterus,	 parametrium,	 and	 the	 placenta.	 This	 will	 result	 in	 secondary	
necrosis	of	the	villous	tissue	and	theoretically	the	placenta	should	pro-
gressively	detach	 itself	 from	the	uterus	and	the	percreta	villi	 from	the	
adjacent pelvic organs.
Two	 separate	 surveys	 from	 the	 Society	 for	 Maternal–Fetal	
Medicine	 (SMFM)22,23	 reported	 that	 14.9%	 of	 practitioners	 would	
attempt	 to	 leave	 the	 placenta	 in	 situ	 in	 a	 hemodynamically	 stable	
patient	and	32%	had	attempted	conservative	expectant	management	
for	 PAS	 disorders.	 In	 an	 older	 survey	 on	 the	 preferences	 for	 surgi-
cal	versus	conservative	therapy	 in	cases	of	placenta	percreta,	 it	was	
found	that	when	adjacent	pelvic	organs	such	as	the	bladder	and	bowel	
are	 involved,	 the	 majority	 of	 members	 of	 the	 Society	 of	 Perinatal	
Obstetricians,	with	and	without	recent	experience	in	the	management	
of	PAS	disorders,	 opt	 for	 conservative	management	 (69%	and	70%,	
respectively)	 compared	with	 31%	when	 the	 accreta	villous	tissue	 is	
confined	to	the	uterus	(creta	or	increta).21
3.1 | Practical issues
In	 cases	 of	 invasive	 PAS	 disorders	 diagnosed	 prenatally,	 the	 exact	
position	of	the	placenta	should	be	determined	by	preoperative	ultra-
sound	and	the	required	surgical	equipment	for	an	emergent	hyster-
ectomy	 should	 available	 in	 the	 operating	 theatre.	 A	 low	 transverse	
skin	 incision	allowing	access	 to	 the	 lower	half	of	 the	uterus	 can	be	
performed	if	the	upper	margin	of	the	anterior	aspect	of	the	placenta	
does	not	rise	into	the	upper	segment	of	the	uterus.	If	the	placenta	is	
anterior	 and	extending	 toward	 the	 level	 of	 the	umbilicus,	 a	midline	
skin	incision	may	be	needed	to	allow	for	a	high	upper-	segment	trans-









uterine	 cavity	 should	 be	 closed.	 Postoperative	 antibiotic	 therapy	 is	
usually	administered	prophylactically	to	minimize	the	risk	of	infection.
A	 literature	 review	 performed	 up	 to	 2007,	 including	 48	 case	
reports	 describing	 the	 outcome	 of	 60	women	 presenting	with	 PAS	
disorders	and	managed	by	leaving	the	placenta	in	situ,	found	that	of	
the	26	women	managed	without	the	use	of	additional	therapies,	22	
(85%)	had	a	favorable	outcome.24 Expectant management failed in 4 
(15%)	cases	and	secondary	hysterectomy	had	to	be	performed	owing	
to	massive	obstetric	hemorrhage	or	infection.24
A	 French	 multicenter	 retrospective	 study	 of	 167	 cases	 of	 PAS	
disorders	managed	 in	40	 teaching	hospitals	 evaluated	 the	maternal	
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outcome	 after	 conservative	 treatment	 and	 found	 that	 25	 (63%)	 of	
the	 centers	 reported	 to	 have	 used	 conservative	 treatment	 for	 PAS	


























review	of	 57	 cases	 from	 the	 literature	 found	 that	when	managed	
conservatively	with	 the	 placenta	 left	 in	 situ,	 hysterectomy	 can	 be	
avoided	in	60%	of	cases.28	However,	42%	of	these	cases	had	major	
complications	 including	 sepsis,	 coagulopathy,	 hemorrhage,	 pulmo-
nary	embolism,	fistula,	and	arteriovenous	malformation.	In	another	
review,	 in	 36	 cases	 of	 placenta	 percreta	 managed	 by	 leaving	 the	




morbidity	was	observed	 in	3	 (16.7%)	 cases.	Of	 the	 eight	 cases	of	
































































Severe maternal morbidity 10	(6.0)
aModified	from	Sentilhes	et	al.2
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these	different	additional	procedures	and	the	quality	of	the	evidence	
varies	according	to	the	type	of	procedure	used.
3.2.1 | Gentle attempted removal of the placenta
In	case	of	false-	positive	prenatal	diagnosis	with	no	clinical	evidence	










cental	 resolution.29	Only	 case	 reports	 and	 small	 case	 series	with	 no	
control	 group	 have	 been	 reported.24	 A	 recent	 observational	 case	



















a	subsequent	pregnancy	 in	one	out	of	 two	cases	 (50%).32 One case 
of	maternal	 death	was	 reported	 in	 the	 French	national	 survey2 and 
disseminated	 intravascular	coagulation	may	develop	requiring	a	sec-
ondary	hysterectomy.33	Overall,	 the	use	of	methotrexate	 is	not	 rec-
ommended	until	further	evidence	is	available	on	its	efficacy	and	safety.
3.2.3 | Preventive surgical or radiological  
uterine devascularization
There	are	also	very	 limited	data	on	the	use	of	 these	adjuvant	 tech-
niques.34–44	Preventive	devascularization	can	be	achieved	by	surgical	
or	interventional	radiology	procedures	also	used	in	the	management	
of	 severe	 postpartum	 hemorrhage,	 such	 as	 stepwise	 uterine	 surgi-








success	 rates	 of	 90%	 for	 arterial	 embolization,	with	 secondary	 hys-
terectomy	 necessary	 in	 only	 11.3%.39	 In	 the	 remaining	 85	women,	






arteries in cases of PAS disorders is even more controversial, mainly 
owing	 to	 the	higher	 risks	of	 complications	 than	with	embolization.	 In	
particular,	there	are	two	case	reports,	one	of	a	popliteal	and	one	of	an	




of	 PAS	 disorders	 reported	 the	 use	 of	 prophylactic	 lower	 abdominal	
aorta balloon occlusion and found a reduced need for blood transfu-
sion.43	One	of	the	cases	was	complicated	by	lower	extremity	arterial	










claudication	 and	 abdominal	 pain	 in	 the	 other).44	 Larger	 studies	 and	
randomized	controlled	 trials	are	essential	 to	demonstrate	 the	safety	
and	efficacy	of	prophylactic	bilateral	iliac	balloon	occlusion	before	this	
technique	can	be	offered	in	the	management	of	PAS	disorders.








after	 one,	 two,	 and	 three	 hysteroscopic	 procedures	 in	 5	 (41.7%),	 2	
(16.7%),	 and	 4	 (33.3%)	 cases,	 respectively.	 These	 results	 suggest	
that	hysteroscopic	 resection	could	 shorten	 the	 recovery	time	with-
out	major	 adverse	 effects.	However,	 in	 this	 series	 all	women	were	
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symptomatic,	 thus	the	role	of	systematic	hysteroscopic	 resection	 in	
asymptomatic	women	remains	to	be	determined.
High-	intensity	 focused	 ultrasound	 (HIFU)	 is	 an	 ultrasound	 heat	
technique	 used	 in	 the	 management	 of	 prostate	 cancer.	 HIFU	 has	
recently	 been	 used	 in	 the	 treatment	 of	 PAS	 disorders	 after	 vaginal	
delivery,	 but	 its	 safety	 and	efficiency	 remain	 to	be	demonstrated	 in	
larger	 prospective	 trials.46	 The	 study	 included	 12	women	with	 PAS	
disorders.	 The	 average	 period	 of	 residual	 placental	 involution	 was	
36.9	days.	HIFU	 treatment	 did	 not	 increase	 the	 risk	 of	 infection	 or	
hemorrhage	 and	 no	 patient	 required	 hysterectomy;	 however,	 the	
authors	did	not	include	histopathology	data,	and	thus	one	can	assume	
that	most	 if	 not	 all	 of	 their	 cases	were	 of	 placenta	 creta	 and/or	 of	
	placental	retention.





to be completely absorbed.31	In	rare	cases,	a	coagulopathy	or	septice-
mia	may	develop,	requiring	an	emergent	secondary	hysterectomy.33 
Measuring serum β-	hCG	on	a	weekly	basis	to	check	it	falls	continu-
ously can reassure to some extent, but low levels do not guarantee 
complete	 placental	 resorption	 and	 so	 this	 should	 be	 supplemented	
by	expert	ultrasound	 imaging.	There	 is	 insufficient	evidence	 to	 rec-
ommend	the	use	of	MRI.38 Subsequent management usually requires 
weekly	 follow-	up	 visits	 during	 the	 first	 2	months	 and	 then	 in	 the	
absence	 of	 complications,	 monthly	 visits	 until	 complete	 resorption	
of	the	placenta.	The	follow-	up	consultation	should	 include	a	clinical	
examination	 (bleeding,	 temperature,	 pelvic	 pain),	 pelvic	 ultrasound	
(size	of	retained	tissue),	and	laboratory	tests	for	infection	(hemoglobin	
and leukocytes count, vaginal sample for bacteriological analysis).2
3.4 | Long- term obstetric and fertility outcomes
Successful	conservative	treatment	for	PAS	disorders	does	not	appear	
to	compromise	subsequent	fertility	or	obstetric	outcome,	but	data	are	
limited. Pregnancies following prior PAS disorders are at increased 
risk for adverse maternal outcomes including recurrent PAS disorders, 
uterine	 rupture,	 postpartum	 hemorrhage,	 and	 peripartum	 hysterec-
tomy.47–49	 Overall,	 the	 risk	 of	 recurrence	 of	 PAS	 disorders	 ranges	
between	 22%50	 and	 29%,49	 whereas	 the	 risk	 of	 early	 postpartum	
hemorrhage	 ranges	 between	8.6%50	 and	 19%.49	 Long-	term	 compli-
cations	 also	 include	 intrauterine	 adhesions	 and	 secondary	 amenor-
rhea,49	which	both	have	a	direct	effect	on	fertility.
All	 women	 included	 in	 the	 French	 national	 retrospective	 study	
who	did	not	undergo	a	hysterectomy	were	contacted	to	evaluate	their	
fertility	 and	 pregnancy	 outcomes	 after	 successful	 expectant	 man-
agement.49	Follow-	up	data	were	available	for	96	of	the	131	women	
(73.3%)	included	in	the	study.	Eight	(8.3%)	women	had	severe	intra-










4  | ALTERNATIVE CONSERVATIVE 
SURGICAL PROCEDURES
4.1 | One- step conservative surgery














(n=22;	 group	2),	 uterine	preservation	was	 achieved	 in	44	out	of	46	
(95.7%)	and	6	out	of	22	(27.3%)	cases,	respectively.3	The	indications	
for	 the	 18	 hysterectomies	 were	 segmental	 circumferential	 rupture	
greater	 than	 50%	 (n=13),	 coagulopathy	 (n=2),	 infection	 (n=1),	 and	
uncontrolled	 hemodynamic	 instability	 (n=2).	 Among	 the	 50	women	
with	 uterine	 preservation,	 follow-	up	 was	 available	 for	 42	 patients.	
A	 normal	menstrual	 cycle	 returned	 between	 3	 and	 16	months.	 Ten	
women	 had	 another	 uneventful	 pregnancy	 and	 delivery	 with	 no	
 recurrence of PAS disorders.
A	recent	prospective	study	of	71	patients	presenting	with	placenta	
percreta	evaluated	a	variation	of	 the	stepwise	approach	 (Box	2)	and	










6. Bladder repair if necessary.
a	Modified	from	Palacios-	Jaraquemada.52




and	secondly	by	 stitch	occlusion	of	 the	colpo-	uterine	vessels	 in	 the	









4.2 | The Triple- P procedure
A	novel	uterine-	sparing	procedure	for	PAS	disorders	called	the	“Triple-	P	
procedure”	was	 recently	proposed.4,55	The	aim	of	 this	procedure	 is	 to	






















needed	 to	 perform	 the	 technique	was	 5.4	±	0.6	minutes.	 The	 com-
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5  | RECOMMENDATIONS
Recommendations	for	conservative	management	of	PAS	disorders	are	
given in Table 2.
CONSENSUS PANEL
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